BioXcel Therapeutics Inc Reports Q3 2024 Earnings Net Revenue at 214K, Net Loss Narrows to 13.7M

BTAI Stock  USD 0.43  0.02  4.88%   
Under 58% of all BioXcel Therapeutics' traders are looking to take a long position. The analysis of the overall investor sentiment regarding BioXcel Therapeutics suggests that some traders are interested. BioXcel Therapeutics' investing sentiment shows overall attitude of investors towards BioXcel Therapeutics.
  
Net Revenue Reported 214 thousand for Q3 2024, falling short of the estimated 0.76 million, and down from 341 thousand in Q3 2023.Cost of Goods Sold Incre

Read at gurufocus.com
Gurufocus Stories at Macroaxis
  

BioXcel Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards BioXcel Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

BioXcel Therapeutics Fundamental Analysis

We analyze BioXcel Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioXcel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioXcel Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash Per Share

Cash Per Share Comparative Analysis

BioXcel Therapeutics is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

BioXcel Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioXcel Therapeutics stock to make a market-neutral strategy. Peer analysis of BioXcel Therapeutics could also be used in its relative valuation, which is a method of valuing BioXcel Therapeutics by comparing valuation metrics with similar companies.

Peers

BioXcel Therapeutics Related Equities

APLSApellis Pharmaceuticals   4.39   
0%
73.0%
ABOSAcumen Pharmaceuticals   3.52   
0%
58.0%
INZYInozyme Pharma   2.95   
0%
49.0%
TGTXTG Therapeutics   0.83   
0%
13.0%
MREOMereo BioPharma   0.55   
0%
9.0%
AMLXAmylyx Pharmaceuticals   0.18   
0%
3.0%
DAWNDay One   0.65   
10.0%
0%
TERNTerns Pharmaceuticals   1.44   
24.0%
0%
EXELExelixis   2.39   
40.0%
0%
VKTXViking Therapeutics   2.70   
45.0%
0%
MDGLMadrigal Pharmaceuticals   2.94   
49.0%
0%
ELEVElevation Oncology   3.13   
52.0%
0%
XFORX4 Pharmaceuticals   5.13   
85.0%
0%
HEPAHepion Pharmaceuticals   5.97   
100.0%
0%

Complementary Tools for BioXcel Stock analysis

When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Volatility Analysis
Get historical volatility and risk analysis based on latest market data